Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04774445

Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes

This protocol aims to evaluate the efficacy of a theoretically and stakeholder informed patient-centered genetic Interactive Health Communication Application to increase patient understanding of, and affective and behavioral responses to genetic testing. The study investigators hypothesize that the intervention will be associated with increases in knowledge, decreases in distress, increases in communication with relatives and health care providers, and increases in performance of risk reducing health behaviors.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Abramson Cancer Center at the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

About this study

As clinical practice increasingly use multi-gene testing, many patients are left with unknowns after genetic testing. Many have results that are unclear and may or may not be associated with any risk for cancer (Variants of Uncertain Significance), or mutations in genes with very limited information about disease risk or the best medical management. Importantly, many of these uncertainties will be clarified over time, but there is a need for effective ways of communicating these updates to patients who had testing months or years ago. In some cases, there may be multiple updates over time. To address this, this study will provide patients access, using an Interactive Health Communication Application, MyCancerGene, to information about their genetic testing, their specific results and the implications, the ability to print reports and other materials for their relatives and other health care providers and to assess if there has been a change in the personal or family history. Additionally, patients can contact their genetic provider through MyCancerGene and the cancer genetics team can send out updates to patients about their individual results or about new information about risk estimates or screening recommendations. The study investigators hypothesize that MyCancerGene will be associated with increases in knowledge, decreases in distress, increases in communication with relatives and health care providers, and increases in cancer screening and risk reducing health behaviors. After 12 months, all patients will have access to MyCancerGene, which will aid in understanding who benefits most and least from this intervention.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older
  • English Speaking
  • Male or Female
  • Internet and/or mobile access
  • Previously received clinical genetic counseling and testing for hereditary cancer syndromes (up to 60 days prior to recruitment)

Exclusion criteria

•No internet and/or mobile access

Treatment and study plan

MyCancerGene

Behavioral

Interactive Health Communication Application

Primary outcomes

  1. The KnowGene Scale

    Time frame: Baseline - 18 Months

    Change in Knowledge. Score Range = 0-16. Higher score = Better outcome

  2. Patient Reported Outcomes Measurement Information System (PROMIS)

    Time frame: Baseline - 18 Months

    Change in General Anxiety and Depression. Score Range = 4-20 for Anxiety/4-20 for Depression. Lower score = Better outcome

Secondary outcomes

  1. Multi-dimensional Impact of Cancer Risk Assessment Questionnaire (MICRA)

    Time frame: Baseline - 18 Months

    Change in Uncertainty. Score Range = 0-85. Lower score = Better outcome

  2. Impact of Events Scale (IES)

    Time frame: Baseline - 18 months

    Change in Disease-Specific Distress. Score Range =0-40. Lower score = Better outcome

  3. Test Result Recall

    Time frame: Baseline - 18 months

    Single item assessing participants' ability to accurately recall their genetic test result. Single answer multiple choice: Positive, Negative, Variant of Uncertain Significance

  4. Perceptions of Genetic Disease

    Time frame: Baseline - 18 months

    Quantitative scales assessing changes in perceived risk, timeline and utility.

  5. Behavioral Risk Factor Surveillance System Questionnaire (BRFSS)

    Time frame: Baseline - 18 months

    Changes in modifiable cancer lifestyle behaviors. Yes/No responses.

  6. Health and Diet Survey Dietary Guidelines Supplement

    Time frame: Baseline - 18 months

    Changes in diet and exercise. Yes/No responses.

  7. Sharing Genomic Information with Relatives (adapted from the PHENX Toolkit)

    Time frame: Baseline - 18 months

    Assesses the number of relatives and health care providers patients share genetic test results with

Sponsors and collaborators

Lead sponsor

Abramson Cancer Center at Penn Medicine

Other

Collaborators

  • American Cancer Society, Inc.

Registry information

Acronym: MyCancerGene

Important dates

Study start
2021
Primary completion
2025
Study completion
2026
First posted
Mar 1, 2021
Registry last updated
Feb 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.